STOCK TITAN
  1. Home
  2. News
  3. MOTS

MOTUS GI HOLDINGS INC - MOTS STOCK NEWS

Welcome to our dedicated page for MOTUS GI HOLDINGS news (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on MOTUS GI HOLDINGS stock.

Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company headquartered in the United States with subsidiaries in the U.S. and Israel. The company is committed to enhancing endoscopy outcomes, reducing costs, and improving patient experiences. A primary focus of Motus GI is the development and commercialization of the Pure-Vu® System.

The Pure-Vu® System is a medical device designed to improve the colonoscopy experience by aiding in the early detection and prevention of colorectal cancer and other diseases of the colon and rectum. This innovative system, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe, integrates with standard colonoscopes. It facilitates cleaning of a poorly prepared colon during the colonoscopy procedure while maintaining the standard workflow and techniques.

Recent achievements of Motus GI include strengthening their market presence through strategic partnerships and ongoing projects aimed at enhancing the Pure-Vu® System’s functionality and reach. The company continues to focus on securing additional regulatory approvals, expanding its market base, and improving its financial performance.

News

Motus GI Announces 1-for-15 Reverse Stock Split

Rhea-AI Summary
Motus GI Holdings, Inc. will effect a 1-for-15 reverse stock split of its outstanding common stock to increase the per share trading price and meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will result in every fifteen pre-split shares of common stock becoming one share, reducing the number of shares from approximately 8.7 million to approximately 0.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.12%
Tags
none
-
News

Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

Rhea-AI Summary
Motus GI receives FDA clearance for new Pure-Vu EVS Gastro and Gen 4 Colon system, opening opportunities in the Upper GI market and improving endoscopic outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.64%
Tags
clinical trial
-
News

Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon

Rhea-AI Summary
Motus GI Holdings submits special 510(k) for market clearance of its Pure-Vu Gen 4 Gastro and Colon, targeting the Upper GI market and reducing cost-of-goods by 50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
News

Motus GI Amends Royalty Agreement

Rhea-AI Summary
Motus GI cancels royalty rights in exchange for common stock, eliminating $1.0M in contingent royalty obligations from balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
News

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

Rhea-AI Summary
Motus GI Holdings, Inc. announces the appointment of Scott Durbin to its Board of Directors. David Hochman and Darren Sherman have resigned from the Board due to time requirements of their roles at Orchestra BioMed Holdings, Inc. Scott Durbin's extensive experience in finance and clinical development is expected to bring value to Motus GI. The company aims to secure FDA clearance for its next generation system. Durbin's appointment and the focus on expanding Pure-Vu System's capabilities could positively impact stockholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
management
-
News

Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Motus GI Holdings, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
News

Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
MOTUS GI Holdings, Inc. (NASDAQ: MOTS) reported financial results for Q2 2023 and corporate updates. They are on track to submit a special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA, with system wide approval in Banner Medical Hospital Network. The company aims to target strategic and financing alternatives to accelerate commercialization of the Pure-Vu System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
earnings
-
News

Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System

Rhea-AI Summary
Motus GI receives approval to initiate commercial sales of Pure-Vu EVS System in Israel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
-
News

Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center

Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) Implements Pure-Vu System at Banner Desert Medical Center to Improve GI Endoscopy Procedures
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
News

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center

Rhea-AI Summary
Motus GI announced that the Pure-Vu Gen 4 Gastro and Colon system was featured in a live case during an underwater large polyp resection in the colon at the 9th Ecuadorian Institute of Digestive Diseases (IECED) Live Endoscopy Course 2023. Over 1,000 physicians registered for the course. The Pure-Vu Gen 4 system will have a new mode called 'fluid only' to support the new use case of underwater endoscopic mucosal resection (UEMR).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none

FAQ

What is the current stock price of MOTUS GI HOLDINGS (MOTS)?

The current stock price of MOTUS GI HOLDINGS (MOTS) is $0.0251 as of October 15, 2024.

What is the market cap of MOTUS GI HOLDINGS (MOTS)?

The market cap of MOTUS GI HOLDINGS (MOTS) is approximately 435.1K.

What is Motus GI Holdings, Inc.?

Motus GI Holdings, Inc. is a U.S.-based medical technology company focused on improving endoscopy outcomes and patient experiences.

What product is Motus GI known for?

Motus GI is known for the Pure-Vu® System, a device designed to improve the colonoscopy process.

What does the Pure-Vu® System do?

The Pure-Vu® System aids in cleaning a poorly prepared colon during a colonoscopy, facilitating early disease detection and prevention while preserving standard procedural techniques.

Is the Pure-Vu® System approved for use?

Yes, the Pure-Vu® System has received 510(k) clearance from the U.S. FDA and CE Mark approval in Europe.

Where is Motus GI Holdings, Inc. located?

Motus GI Holdings, Inc. is headquartered in the United States with subsidiaries in the U.S. and Israel.

What are the recent achievements of Motus GI?

Recent achievements include market expansion efforts, strategic partnerships, and ongoing development projects for the Pure-Vu® System.

What is the primary focus of Motus GI's current projects?

Current projects are focused on enhancing the Pure-Vu® System’s functionality and securing more regulatory approvals.

How does the Pure-Vu® System integrate with colonoscopes?

The Pure-Vu® System integrates with standard colonoscopes to clean the colon during the procedure, maintaining the standard workflow and techniques.

How does Motus GI contribute to healthcare cost reduction?

By improving the colonoscopy process and reducing the need for repeat procedures, Motus GI helps lower healthcare costs.

Who can I contact for investor information about Motus GI?

For investor information, contact Troy Williams at LifeSci Advisors via phone at (518) 221-0106 or email at twilliams@lifesciadvisors.com.

Stock MOTS logo
MOTUS GI HOLDINGS INC

Nasdaq:MOTS

MOTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MOTS Stock Data

435.11k
6.33M
0.9%
0.01%
0.45%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
FT. LAUDERDALE